Glutamate receptor activation triggers OPA1 release and induces apoptotic cell death in ischemic rat retina by Ju, Won-Kyu et al.
Glutamate receptor activation triggers OPA1 release and induces
apoptotic cell death in ischemic rat retina
Won-Kyu Ju, James D. Lindsey, Mila Angert, Ankur Patel, Robert N. Weinreb
Hamilton Glaucoma Center and Department of Ophthalmology, University of California San Diego, La Jolla, CA
Purpose: Glutamate receptor activation-induced excitotoxicity has been hypothesized to cause retinal ganglion cell (RGC)
death in glaucoma and to link mitochondrial dysfunction in both acute and chronic neurodegenerative disorders. However,
the  relationships  among  elevated  intraocular  pressure  (IOP),  glutamate  receptor-mediated  excitotoxicity,  and
mitochondrial dysfunction in glaucoma remains unknown. The goal of this study was to determine whether the N- methyl
D-aspartate (NMDA) glutamate receptor antagonist MK801 can block optic atrophy 1 (OPA1) release and subsequent
apoptotic cell death, as well as whether acute IOP elevation triggers OPA1 release and alters OPA1 gene and protein
expression in the rat retina after ischemia.
Methods: Sprague Dawley rats received injections of MK801 (10 mg/kg) or vehicle and then transient retinal ischemia
was induced by acute IOP elevation. Following subcellular fractionation, changes in cytoplasmic and mitochondrial OPA1
were assessed by western blot analysis. Also, the expression of OPA1 mRNA was measured by Taqman qPCR, the
distribution of OPA1 protein was assessed by immunohistochemistry, and apoptotic cell death was assessed by terminal
deoxynucleotidyl transferase dUTP nick end labeling (TUNEL) staining.
Results: The ~65 and 90 kDa isoforms of OPA1 were increased in the cytosol in the rat retina at 6 h and at 12 h, but only
the 90 kDa isoform of OPA1 was decreased at 12 h after ischemia induced by acute IOP elevation. This suggests that
ischemic insult induced OPA1 release from the mitochondria in retinas. Pretreatment with MK801 blocked this effect and
significantly increased OPA1 immunoreactivity in the inner retinal layers, as well as OPA1 gene expression and total
protein expression in retinas at 12 h after ischemia. Further, pretreatment with MK801 prevented apoptotic cell death in
retinas at 12 h after ischemia. Following acute IOP elevation, Bcl-2 mRNA expression in retinas was decreased at 3 h and
6 h but increased at 12 h and 24 h. In contrast, Bax mRNA expression in these retinas was increased in the first 12 h and
then plateaued. Moreover, pretreatment with MK801 increased Bcl-2 mRNA expression, but did not alter the course of Bax
mRNA expression.
Conclusions: These results indicate that OPA1 release from mitochondria triggered by acute IOP elevation is inhibited
by blockade of glutamate receptor activation. Because this effect was accompanied by increases of Bcl-2 expression, no
changes of Bax expression, and blockade of apoptosis, these findings indicate that glutamate receptor activation following
acute IOP elevation may lead to a distinct mitochondria-mediated cell death pathway in ischemic retina. These results
support further studies to determine whether ischemia-induced OPA1 release may be an important component of the
biochemical cascade leading to pressure-related ischemic damage in glaucomatous retina.
Elevated intraocular pressure (IOP) is an important risk
factor for optic nerve damage in glaucoma [1]. However, the
precise pathophysiological relationship between elevated IOP
and  retinal  ganglion  cell  (RGC)  death  remains  poorly
understood. It has been hypothesized that glutamate receptor
activation may contribute to RGC death in glaucoma [2]. In
addition, glutamate receptor activation-induced excitotoxicity
has been linked to mitochondrial dysfunction in both acute
and chronic neurodegenerative disorders [3-6]. However, the
relationship among elevated IOP, glutamate excitotoxicity,
and  mitochondrial  dysfunction  in  glaucoma  remains
unknown. Recently, we reported that moderately elevated
hydrostatic pressure could induce abnormal cristae depletion,
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cytochrome  C  release,  cellular  ATP  reduction,  and
translocation  of  dynamin-related  protein-1  (Drp-1)  in
differentiated RGC-5 cells [7]. Further, we also found that
elevated hydrostatic pressure triggers release of optic atrophy
type  1  protein  (OPA1)  and  cytochrome  C,  and  induces
subsequent apoptotic cell death in differentiated RGC-5 cells
[8]. These observations raise the possibility that pressure-
induced mitochondrial dysfunction may contribute to RGC
death in glaucoma.
In  healthy  cells,  mitochondria  are  autonomous  and
morphologically dynamic organelles that structurally reflect
a precise balance of ongoing fission and fusion within a cell
[9-11]. This balance is regulated by a family of dynamin-
related GTPases that exert opposing effects. Drp-1 regulates
mitochondrial fission, while OPA1, the human ortholog of
Mgm1p/Msp1p,  and  the  mitofusins  are  required  for
mitochondria  fusion  [10,12].  OPA1  mRNA  is  transcribed
from nuclear DNA and new OPA1 protein is then translocated
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2629to the inner membrane of mitochondria [13,14]. Of particular
interest, mutations in OPA1 are linked with neurodegenerative
diseases in human and can cause autosomal dominant optic
atrophy (ADOA), the most common form of hereditary optic
neuropathy [15,16]. Retinal OPA1 is expressed in the soma
and axons of the RGCs as well as in horizontal cells [17-19].
Although the specific functional role of OPA1 in these cells
remains unknown, it has been shown that down-regulation of
OPA1 causes mitochondrial fission, leading to cytochrome C
release  and  apoptosis  in  HeLa  cells,  as  well  as  induces
aggregation of the mitochondrial network in purified RGCs
[20-23]. Proteolytic processing of OPA1 has been observed
during  mitochondrial  fission,  although  its  significance
remains  poorly  investigated  [24-27].  Also,  OPA1  release
during  mitochondrial  fission  contributes  to  apoptotic  cell
death [22,26]. Nevertheless, it is unknown whether acute IOP
elevation can directly alter OPA1 expression and distribution
in the mammalian retina.
Thus, we evaluated whether the N- methyl D-aspartate
(NMDA) glutamate receptor antagonist MK801 can block
OPA1 release and subsequent apoptotic cell death as well as
whether acute IOP elevation triggers OPA1 release and alters
OPA1  gene  and  protein  expression  in  the  rat  retina  after
ischemia. Also, we compared the progression of these changes
with changes in Bcl-2 and Bax expression.
METHODS
Transient  retinal  ischemia:  All  procedures  were  in
compliance with the National Institute of Health Guide for the
Care  and  Use  of  Laboratory  Animals  and  the  ARVO
Statement on the Use of Animals in Ophthalmic Research.
Sprague-Dawley female rats, 3 months of age (200–250 g in
weight) were anesthetized with ketamine (100 mg/kg) and
xylazine (20 mg/kg, i.p. injection). A cannula was inserted
into  the  anterior  chamber  that  was  connected  by  flexible
tubing  to  a  reservoir.  By  raising  the  reservoir,  IOP  was
elevated above systolic blood pressure (100–120 mmHg) for
60 min. Animals were allowed to recover for 3 to 24 h.
Pharmacological treatment: Two groups of rats were studied
following unilateral transient retinal ischemia: a group treated
with vehicle (0.9% saline, i.p. injection) and a group treated
with MK801 (10 mg/kg in 0.9% saline; i.p. injection; n=5
animals/group; Sigma, St. Louis, MO) given 30 min before
ischemia.
Tissue preparations: The light-adapted rats were anesthetized
with isoflurane followed by an i.p. injection of ketamine/
xylazine as above. Both eyes were enucleated and then the rats
were killed by CO2 inhalation. The retinas were dissected from
the choroid and fixed in the 4% paraformaldehyde in 0.1 M
phosphate buffer (PB, pH 7.4) for 2 h at 4 °C. Retinas were
dehydrated through graded ethanols and then embedded in
polyester wax [18].
Western blot analysis: The retinas were homogenized in a
glass-teflon Potter homogenizer in lysis buffer (20 mM Hepes,
pH 7.5, 10 mM KCl, 1.5 mM MgCl2, 1 mM EDTA, 1 mM
EGTA,  1  mM  DTT,  0.5%  CHAPS,  complete  protease
inhibitors;  Roche  Biochemicals,  Indianapolis,  IN).  Each
sample  (10  µg)  was  separated  by  PAGE  and  electro-
transferred to Polyvinylidene Fluoride (PVDF) membranes.
The membrane was blocked with 5% nonfat dry milk and
0.05%  in  Tween-20  in  phosphate  buffer  saline  (PBS),
incubated  with  monoclonal  mouse  anti-OPA1  antibody
(H-300/1:1000; BD Transduction Laboratories, San Diego,
CA) or monoclonal mouse anti-actin antibody (Ab-1/1:3,000;
Calbiochem, La Jolla, CA), rinsed with 0.05% Tween-20 in
PBS, incubated with peroxidase-conjugated goat anti-mouse
IgG (1:2,000; Bio-Rad, Hercules, CA), or goat anti-rabbit IgM
(1:5,000;  Calbiochem),  and  developed  using
chemiluminescence detection (ECL Plus; GE Healthcare Bio-
Sciences, Picataway, NJ). Images were analyzed by digital
fluorescence  imager  (Storm  860;  GE  Healthcare  Bio-
Sciences) and band densities were normalized using actin as
cytosolic fraction calibrator and Voltage-dependent Anion
Channel (VDAC) as mitochondrial fraction calibrator with
ImageQuant TL (GE Healthcare Bio-Sciences).
To  assess  the  subcellular  distribution  of  OPA1,  the
cytosolic  and  mitochondrial  fractions  were  isolated  from
retinas by differential centrifugation (Mitochondrial Isolation
Kit;  Pierce,  Rockford,  IL)  and  western  blot  analysis  was
performed  as  above.  Equal  loading  was  confirmed  by
reprobing with actin as above or with polyclonal rabbit anti-
VDAC antibody (Ab-5/1:1,000, Calbiochem).
Taqman quantitative polymerase chain reaction: Total RNA
from retinas was extracted with Trizol (Invitrogen, Carlsbad,
CA), purified on RNeasy mini columns (Qiagen, Valencia,
CA), and treated with RNase-free DNase I (Qiagen). OPA1,
Bax, and Bcl-2 gene expression were measured by Taqman
quantitative PCR (MX3000P, Stratagene, La Jolla, CA) using
50 ng of cDNA from retinas and 2X Taqman universal PCR
master mix (Applied Biosystems, Foster City, CA) with a one-
step program (95 °C for 10 min, 95 °C for 30 s, and 60 °C for
1 min for 50 cycles). Primers for OPA1, Bax, Bcl-2, and
GAPDH, as well as Taqman probe for GAPDH were designed
using  Primer  Express  2.0  software  (Applied  Biosystems),
obtained  from  Roche  Diagnostics  (Mannheim,  Germany;
Table 1), and the optimal concentrations for probe and primers
were  determined  using  heart  tissue.  Duplicate  samples
without  cDNA  (no-template  control)  showed  no
contaminating DNA. Standard curves were constructed using
nine twofold dilutions (50 ng-0.195 ng) for both the targets
(OPA1,  Bax  and  Bcl-2)  and  the  endogenous  reference
(GAPDH). The samples were run in triplicates for target and
endogenous GAPDH control.
Immunohistochemical  analysis:  Immunohistochemical
staining 7 μm wax section of full thickness retina was done
by the Tyramide Signal Amplication Kit (Molecular Probes,
Eugene,  OR)  as  described  below  [18].  To  increase  the
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to primary and secondary antibodies were incubated with
solutions  from  the  Tyramide  Signal  Amplification  Kit
(Molecular Probes). Tissues were permeabilized with 0.1%
Triton  X-100  in  PBS,  incubated  with  quenching  buffer
(Amplication  buffer  and  0.0015%  H2O2)  for  1  h  at  room
temperature, blocked with 1% BSA/PBS, and then incubated
with antibody against OPA1 (provided by Drs. Misaka and
Kubo, University of Tokyo, 1:100) for 16 h at 4 °C. After
several  washing,  tissues  were  incubated  with  peroxidase-
conjugated goat anti-rabbit IgG for 1 h at room temperature,
washed, and incubated with tyramide working solution for 10
min at room temperature.
TUNEL staining: Sections were incubated with proteinase K
(10 µg/ml, 10 mM Tris, pH 7.4–8.0) for 10 min at 37 °C. After
rinsing in PBS, the sections were incubated with terminal
deoxynucleotidyl  transferase  plus  nucleotide  mixture  in
reaction  buffer  for  60  min  at  37  °C  (In  situ  Cell  Death
Detection kit, Roche Diagnostics).
Statistical analysis: Experiments presented were repeated at
least  three  times  with  triplicate  samples.  The  data  are
presented as the mean±SD. Comparison of two experimental
conditions was evaluated using the unpaired Student’s t-test.
A p<0.05 was considered to be statistically significant.
RESULTS
Acute intraocular pressure elevation induces OPA1 release
from mitochondria in the rat retina: The OPA1 antibody
recognized a major band (80 kDa) in the cytosolic fraction and
two major bands (90 and 80 kDa) in the mitochondrial fraction
of  the  normal  rat  retina.  After  ischemia,  at  least  4  major
isoforms of OPA1 (90 kDa:L, 80 kDa:S1, ~75 kDa:S2, and
~65  kDa:S3)  were  observed  in  the  cytosolic  fraction.  In
contrast, only 2 major isoforms of OPA1 (L and S1) were
observed in the mitochondrial fraction (Figure 1A). Increased
L and S3 isoforms were prominent in the cytosolic fraction at
6 h and at 12 h after ischemia but there were no changes in the
S1  and  S2  isoforms.  In  the  mitochondrial  fraction  from
ischemic retina, L isoform OPA1 was significantly decreased
at 12 h but there was no significant change in S1 isoform
OPA1 (Figure 1B).
Blockade of glutamate receptor activation increases OPA1
gene  and  protein  expression  in  the  rat  retina  following
transient ischemia: OPA1 mRNA expression did not differ in
vehicle-pretreated retina after ischemia, compared to normal
retina.  However,  pretreatment  with  MK801  significantly
increased OPA1 mRNA expression by 26.0±1.1% in retina
after ischemia (Figure 2A). Interestingly, pretreatment with
MK801 significantly increased total L and S1 isoforms of
OPA1 protein at 12 h of ischemic retina but significantly
decreased total S3 isoform of OPA1 protein (Figure 2B,C).
OPA1 immunoreactivity was localized in the ganglion cell
layer (GCL), inner plexiform layer (IPL), inner nuclear layer
(INL), and outer plexiform layer (OPL) in the normal rat retina
as previously reported (Figure 2D) [18]. In ischemic rat retina
pretreated with vehicle, OPA1 immunoreactivity in the GCL,
IPL, INL, and OPL did not show significant changes at 12 h
(Figure  2E).  In  contrast,  pretreatment  with  MK801
significantly increased OPA1 immunoreactivity in the IPL,
INL, and OPL at 12 h after ischemia (Figure 2F). In addition,
we found that there were no significant changes of both OPA1
mRNA  and  protein  expression  level  between  two  control
conditions (non-pressurized retina and non-pressurized retina
plus MK801; Figure 3).
TABLE 1. PRIMER AND PROBE SEQUENCES FOR OPA1, BAX, BCL-2, AND GAPDH FOR TAQMAN QUANTITATIVE PCR .
Gene (GenBank) Type Sequences (5′–3′)
OPA1 rat (NM_133585) Forward CAGCTGGCAGAAGATCTCAAG
  Reverse CATGAGCAGGATTTTGACACC
  Probe Universal Probe Library probe #2
    Cat. # 04684982001
Bax rat (NM_017059) Forward GTGAGCGGCTGCTTGTCT
  Reverse GTGAGCGGCTGC-TTGTCT
  Probe Universal Probe Library probe #83
    Cat. # 04689062001
Bcl-2 rat (NM_016993) Forward GGGATGCCTTTGTGGAACT
  Reverse CTGAGCAGCGTCTTCAGAGA
  Probe Universal Probe Library probe #2
    Cat. # 04684982001
GAPDH rat (X02231) Forward GAACATCATCCCTGCATCCA
  Reverse CCAGTGAGCTTCCCGTTCA
  Probe CTTGCCCACAGCCTTGGCAGC
aTaqman probe containing 5′ reporter FAM and 3′ quencher BHQ-1 dyes.
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aBlockade  of  glutamate  receptor  activation  significantly
prevents OPA1 release in the rat retina following transient
ischemia: In ischemic retina pretreated with vehicle, the L and
S3  isoforms  of  OPA1  were  significantly  increased  in  the
cytosolic fraction (Figure 4A,B). In contrast, the L isoform
was  significantly  decreased  in  the  mitochondrial  fraction
(Figure 4A,B). Pretreatment with MK801 blocked all of these
ischemia-induced  changes  in  cytosolic  OPA1.  Moreover,
pretreatment with MK801 significantly increased both L and
S1  isoforms  OPA1  in  the  mitochondrial  fraction  (Figure
4A,B).
Blockade of glutamate receptor activation inhibits apoptotic
cell death, and increased Bcl-2 expression but did not alter
Bax expression: In normal retina, there were no TUNEL-
positive  cells  (Figure  5A).  Ischemic  insult  by  acute  IOP
elevation induced apoptotic cell death in the GCL, INL, and
ONL  at  12  h  (Figure  5B).  In  contrast,  pretreatment  with
MK801  blocked  this  apoptosis  in  all  layers  following
ischemia (Figure 5C). Bcl-2 mRNA was decreased in early
Figure 1. Acute IOP elevation induces
OPA1 release in ischemic rat retina. A:
The OPA1 protein bands observed at
80 kDa in cytosolic fraction and at 80
and  90  kDa  forms  in  mitochondrial
fraction  of  normal  retina.  Following
ischemia, there were at least four major
isoforms of OPA1 protein bands (90:L,
80:S1, ~75:S2, and ~65 kDa:S3) in the
cytosolic fraction. B: Relative intensity
of chemiluminescence for each protein
band  was  normalized  using  actin  as
cytosolic fraction calibrator and VDAC
as mitochondrial fraction calibrator. The
isoforms of OPA1 protein (L and S3)
were  significantly  increased  in  the
cytosolic  fraction.  However,  the
isoform  of  OPA1  protein  (L)  was
significantly decreased at 12 h but the
isoform of OPA1 protein (S1) was not
changed in the mitochondrial fraction at
6–24  h  after  ischemia.  Error  bars
represent  the  standard  deviation
(*p<0.05 by Student’s t-test, n=3).
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24  h)  in  vehicle-pretreated  ischemic  retina,  compared  to
normal  retina  (Figure  5D).  In  addition,  pretreatment  with
MK801 significantly increased Bcl-2 mRNA expression by
31.0±2.7%  at  12  h  (Figure  5E),  compared  to  vehicle-
pretreated  ischemic  retina.  Bax  mRNA  expression  was
increased earlier than Bcl-2 and plateaued by 12 h in vehicle-
pretreated  ischemic  retina  (Figure  5F).  Pretreatment  with
MK801 did not significantly change Bax mRNA expression
at 12 h (Figure 5G), compared to vehicle-pretreated ischemic
retina.
DISCUSSION
Our results demonstrate that (1) ischemic insult by acute IOP
elevation  triggers  OPA1  release  in  the  early
neurodegenerative  events  (within  12  h),  (2)  blockade  of
glutamate  receptor  activation  prevents  OPA1  release  and
apoptotic cell death as well as increases OPA1 gene and total
protein expression at 12 h after ischemia, and (3) blockade of
glutamate  receptor  activation  induces  increases  of  Bcl-2
expression but no changes of Bax expression at 12 h after
ischemia.  These  findings  indicate  that  glutamate  receptor
activation following acute IOP elevation may lead to a distinct
mitochondria-mediated cell death pathway in ischemic retina.
Further,  this  ischemia-induced  OPA1  release  may  be  an
important component of the biochemical cascade leading to
pressure-related ischemic damage in glaucomatous retina.
Emerging  evidence  indicates  that  mitochondrial
morphology and dynamics play an important role in cell and
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Figure  2.  Blockade  of  glutamate
receptor  activation  increases  OPA1
gene and protein expression in ischemic
rat retina. A: OPA1 gene expression was
not  changed  in  vehicle-pretreated
ischemic  retinas  but  increased  in
MK801-pretreated  ischemic  retinas  at
12 h. B: The total isoformes of OPA1
protein bands (80–90 kDa) in the normal
rat retina were increased after ischemia,
and had a small released fragment of
OPA1 (~65 kDa:S3). Pretreatment with
MK801  induced  a  larger  increase  of
total L and S1 isoforms of OPA1 protein
bands but decrease of total S3 isoform
of  OPA1  protein  band.  C:  Relative
intensity of chemiluminescence for each
protein band was normalized using actin
as  cytosolic  fraction  calibrator.  Error
bars  represent  the  standard  deviation
(*p<0.05 by Student’s t-test, n=3). D-F:
OPA1  immunoreactivity  in  normal
retina (D), retina of vehicle pre-treated
rats at 12 h after ischemia (E), and retina
of MK801 pre-treated rats at 12 h after
ischemia  (F).  Abbreviations:  ONL
represents  outer  nuclear  layer;  OPL
represents  outer  plexiform  layer; INL
represents  inner  nuclear  layer;  IPL
represents inner plexiform layer; GCL
represents ganglion cell layer. The scale
bar represents 20 μm (D-F).animal  physiology.  An  imbalance  in  the  control  of
mitochondrial fusion and fission dramatically alters overall
mitochondrial morphology [11,12]. This balance is regulated
by a family of dynamin-related GTPases that exert opposing
effects. In mammals, OPA1 and mitofusins are required for
mitochondria  fusion.  In  contrast,  Drp-1  regulates
mitochondrial fission [10,12]. Recent evidence indicates that
OPA1 release participates in the rapid and complete release
of cytochrome C in apoptotic cell death as well as controls
apoptotic cristae remodeling [22,26]. In the present study, we
found a small isoform of OPA1 (80 kDa) in the cytosolic
fraction and two isoforms of OPA1 (90 and 80 kDa) in the
mitochondrial fraction of the normal rat retina. In contrast,
ischemic rat retina showed at least four isoforms of OPA1 in
the cytosolic fraction at 6 h and 12 h. Interestingly, while both
90  and  ~65  kDa  isoforms  of  OPA1  were  significantly
increased in the cytosolic fraction, the large isoform of OPA1
(90 kDa) was significantly decreased in the mitochondrial
fraction.  These  results  indicate  that  ischemic  damage
following acute IOP elevation directly induces OPA1 release
from mitochondria to the cytoplasm in the retina. Activation
of rhomboid intramembrane protease (PARL) may explain the
cleavage of OPA1 into truncated forms observed in the present
study following ischemia [28]. OPA1 may be crucial for the
Figure 3. The effect of MK801 in the
normal  rat  retina.  A:  OPA1  gene
expression was not changed in MK801-
pretreated  normal  control  retinas
compared to non-treated normal control
retinas.  B:  The  OPA1  protein  bands
observed  at  80  and  90  kDa  forms  in
cytosolic and mitochondrial fractions in
both  non-treated  and  MK801-treated
normal control retina. Relative intensity
of chemiluminescence for each protein
band  was  normalized  using  actin  as
cytosolic fraction calibrator and VDAC
as  mitochondrial  fraction  calibrator.
Note  that  there  were  no  significant
changes  between  non-treated  and
MK801-treated  normal  control  retina.
Error  bars  represent  the  standard
deviation.
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bottleneck  configuration  of  cristae  and  the
comparmententalization of cytochrome C [25,28]. Thus, it is
likely that the unexpected smaller molecular weight of OPA1
fragments  presently  observed  might  include  the  truncated
forms of OPA1 that localize to in the intermembrane space or
possibly one of the degradation products. Although OPA1
consists  of  at  least  five  isoforms  in  other  types  of  cells
including HeLa cells [29-31], the precise functional role of
the  OPA1  isoforms  that  are  released  from  mitochondria
remains unknown. Thus, the potential proteolytic processing
of OPA1 as well as the functional role of each OPA1 isoform
in the cytosolic and mitochondrial fractions of the ischemic
retina need to be further explored.
OPA1 is ubiquitously expressed in several tissues but is
most  abundant  in  the  retina  [15,17,18].  Pesch  et  al.  [17]
reported that the OPA1 gene is expressed and its protein is
present in RGCs and displaced amacrine cells in the normal
rat retina. Further, we also reported that OPA1 protein is
present in the amacrine cells and RGCs as well as horizontal
cells of the normal rat retina [18]. Like OPA1, glutamate
receptor subunits are present in horizontal cells, bipolar cells,
amacrine cells, displaced amacrine cells, or RGCs in the rat
retina [32-38]. It has been reported that many amacrine cells
in the INL were rapidly and dramatically injured or killed by
glutamate or NMDA and that displaced amacrine cells in the
GCL  also  became  swollen  [38].  Thus,  it  is  possible  that
glutamate  receptor  activation-mediated  excitotoxicity  may
directly or indirectly contribute to neuronal cell death in the
inner  and  outer  retinal  layer.  Moreover,  glutamate
neurotoxicity  is  partly  responsible  for  ischemic  retinal
damage [39-43]. Hence, it is possible that OPA1-positive cells
in the rat retina may also have glutamate receptors.
In  the  present  study,  blockade  of  glutamate  receptor
activation prevented OPA1 release and apoptotic cell death as
well as increased OPA1 gene and total protein expression in
ischemic rat retina. These results are good agreement with
previous  studies  that  down-regulation  of  OPA1  causes
mitochondrial fission, leading to cytochrome C release and
apoptosis in HeLa cells, as well as induces aggregation of the
mitochondrial network in purified RGCs [20-23] and that
increased OPA1 expression protects cells from apoptosis by
preventing cytochrome C release and by stabilizing the shape
of mitochondrial cristae [22,23]. Moreover, OPA1 deficiency
in  mouse  models  of  ADOA  impairs  mitochondrial
morphology, optic nerve structure, and visual function [44,
45]. Together with these findings, our observations suggest
that  alteration  of  OPA1  expression  and  distribution  by
Figure  4.  Blockade  of  glutamate
receptor activation blocks OPA1 release
in  ischemic  rat  retina.  A:  The  OPA1
protein  bands  observed  at  80  kDa  in
cytosolic fraction and at 80 and 90 kDa
forms  in  mitochondrial  fraction  of
normal  retina.  Following  ischemia,
there were at least 4 major isoforms of
OPA1  protein  bands  (90:L,  80:S1,
~75:S2,  and  ~65  kDa:S3)  in  the
cytosolic fraction. B: Relative intensity
of chemiluminescence for each protein
band  was  normalized  using  actin  as
cytosolic fraction calibrator and VDAC
as mitochondrial fraction calibrator. The
isoforms of OPA1 protein (L and S3)
were  significantly  increased  in  the
cytosolic fraction and decreased in the
mitochondrial  fraction  at  12  h  after
ischemia.  Pretreatment  with  MK801
significantly blocks OPA1 release to the
cytosol and increased OPA1 protein in
the  mitochondria  at  12  h  following
ischemia.  Error  bars  represent  the
standard  deviation  (*p<0.05  by
Student’s t-test, n=3).
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neurodegenerative  events  in  ischemic  insult-related
glaucomatous optic neuropathy.
Bax is a proapoptotic member of the Bcl-2 family that is
essential for many pathways of apoptosis [46]. Bax directly
interacts  with  the  components  forming  the  mitochondrial
permeability transition pore (MPTP) that allow proteins to
escape  from  the  mitochondria  into  the  cytosol  to  initiate
apoptosis [47-49]. In the present study, we found that ischemia
induced  significant  increases  of  Bcl-2  and  Bax  mRNA
expression in the retina at 12 h showing apoptotic cell death.
Interestingly, blockade of glutamate receptor activation did
not  alter  the  increase  of  Bax  expression  but  significantly
increased Bcl-2 expression at 12 h. Perhaps, this increased
Bcl-2 may block the Bax-mediated MPTP formation that may
cause OPA1 release from mitochondria in ischemic retina.
These observations suggest that increased OPA1 expression
by blockade of glutamate receptor activation may contribute
to retinal neuron survival in the presence of ischemic stress.
Further studies will be needed to determine the mechanism of
this effect and to clarify the relationships among glutamate
receptor activation, OPA1 release, and increases of Bcl-2 and
Bax following ischemic damage.
In summary, our findings demonstrated that glutamate
receptor  activation  triggers  OPA1  release  in  the  early
neurodegenerative  events  and  that  blockade  of  glutamate
Figure  5.  Blockade  of  glutamate
receptor activation blocks apoptotic cell
death  and  induces  increase  of  Bcl-2
expression  in  ischemic  rat  retina.  A:
There were no TUNEL-positive cells in
the normal retina. B: In ischemic retina
of rats receiving vehicle, apoptotic cell
death was present in the ONL, INL,and
GCL.  C:  MK801  treatment  before
ischemia blocked apoptotic cell death in
all layers. D: Bcl-2 mRNA significantly
decreased at 6 h but increased at 24 h,
compared to normal retinas. E: Bcl-2
mRNA  following  ischemia  was
significantly  increase  at  12  h  by
pretreatment with MK801, compared to
the  vehicle-pretreated  retinas.  F:  Bax
mRNA was significantly increased from
6 to 12 h, compared to normal retina.
G:  No  Bax  expression  following
ischemia  was  shown  at  12  h  by
pretreatment with MK801, compared to
the vehicle-pretreated retinas. Error bars
represent  the  standard  deviation
(*p<0.05  by  Student’s  t-test,  n=3).
Abbreviations:  ONL  represents  outer
nuclear  layer;  OPL  represents  outer
plexiform  layer;  INL  represents  inner
nuclear  layer;  IPL  represents  inner
plexiform  layer;  GCL  represents
ganglion  cell  layer.  The  scale  bar
represents 20 μm (A-C).
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2636receptor activation prevents OPA1 release and apoptotic cell
death as well as increases OPA1 expression and total protein
expression  in  the  ischemic  rat  retina.  This  suggests  that
defined OPA1 distribution changes may be a factor in the
apoptosis  induced  by  glutamate  receptor  activation  in
ischemic retina. Moreover, Bcl-2 and Bax alterations may also
contribute to these events though further study will be needed
to clarify their relationship. Together, these results raise the
possibility that OPA1 release induced by glutamate receptor
activation  contributes  to  mitochondrial  dysfunction  in  the
pathophysiology  of  pressure-related  ischemic  damage  in
glaucomatous retina.
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